Found: 5
Select item for more details and to access through your institution.
Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV‐1 in need of parenteral antiretroviral therapy.
- Published in:
- HIV Medicine, 2023, v. 24, n. 2, p. 202, doi. 10.1111/hiv.13370
- By:
- Publication type:
- Article
Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 11, p. 1060, doi. 10.1002/cpdd.1293
- By:
- Publication type:
- Article
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1–infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study
- Published in:
- Antiviral Therapy, 2024, v. 29, n. 2, p. 1, doi. 10.1177/13596535241248282
- By:
- Publication type:
- Article
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
- Published in:
- AIDS Research & Therapy, 2019, v. 16, n. 1, p. N.PAG, doi. 10.1186/s12981-019-0235-1
- By:
- Publication type:
- Article
Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials.
- Published in:
- Journal of Medical Virology, 2021, v. 93, n. 6, p. 3985, doi. 10.1002/jmv.26721
- By:
- Publication type:
- Article